Abstract 14069: Subclinical Impairment of Left Ventricular Function in Stage A Subjects in a Community-based Population
Introduction: Stage A heart failure (HF) is defined as an asymptomatic state with HF risk factors of hypertension, diabetes, obesity, metabolic syndrome, and atherosclerotic disease in the absence of obvious left ventricular (LV) structural changes including LV hypertrophy (LVH). ACC/AHA guidelines recommend us to treat these risk factors of Stage A HF patients to prevent the progression of HF, hinting us to investigate the prevalence of subclinical impairment of LV function in Stage A subjects in general populations.
Methods: We studied 1162 community-dwelling subjects without obvious heart diseases (mean age, 63±11 years; 448 men, 714 women, 63% with hypertension and 11% with diabetes) in the annual health checkup in a rural community, Arita-cho, Saga, Japan. The population was divided into 3 groups; the subjects without either LVH or the HF risk factors ("Stage 0"), the subjects with the HF risk factors in the absence of LVH (Stage A) , and the subjects in the presence of LVH (Stage B). LV systolic and diastolic function were estimated by mitral annular velocity in systole (s'), and the waves of transmitral flow (E) and mitral annular velocity (e'), respectively. LVH was defined as the top quintile of LV mass index.
Results: The subjects in Stage A had the lower and higher values of s' and E/e', respectively, and the higher prevalence of LV diastolic dysfunction than those in Stage 0, while 45% of Stages A subjects showed LV diastolic dysfunction (Table). In multivariate logistic analyses, age, systolic blood pressure and LV mass were independent determinants of s', whereas either overlapped or different risk factors, such as age, sex, systolic blood pressure, and body mass index emerged as the determinants for E/e'.
Conclusions: Even without obvious LV remodeling, subclinical LV systolic and diastolic impairment was observed in Stage A subjects. The disparity of the risk factors between LV systolic and diastolic dysfunction may indicate their pathophysiological differences.
Author Disclosures: T. Hasegawa: None. M. Asakura: None. H. Kanzaki: None. H. Asanuma: None. S. Takashio: None. M. Amaki: None. H. Takahama: None. T. Ohara: None. Y. Sugano: None. S. Yasuda: None. H. Ogawa: Other Research Support; Modest; Astellas Pharma Inc, Bayer, Bristol-Myers Squibb Company, Chugai Pharmaceutical Co, Ltd., Daiichi Sankyo Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., MSD K.K., Mochida Pharmaceutical Co., Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co., Ltd., Otsuka, Pfizer Japan Inc, Sanofi K.K., Takeda Pharmaceutical Co., Ltd.. Other Research Support; Significant; Modest, Significant, Modest, Modest, Significant, Modest, Modest, Modest, Significant, Modest, Modest, Modest, Significant, Modest. Honoraria; Modest; AstraZeneca K.K., Bayer Yakuhin, Ltd., Boehringer Ingelheim Japan, Bristol-Myers Squibb Company, Daiichi Sankyo Co., Ltd., Mitsubishi Tanabe Pharma, MSD K.K., Pfizer Japan Inc, Sanofi K.K., Takeda Pharmaceutical Co., Ltd., Teijin Pharma Co., Ltd. Honoraria; Significant; Modest, Significant, Modest, Modest, Significant, Modest, Significant, Modest, Modest, Significant, Modest. T. Anzai: None. M. Kitakaze: None.
- © 2015 by American Heart Association, Inc.